References
- Rinkel GJ, Feigin VL, Algra A, Van Gijn J. Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2004;CD000483.
- Kim JH, Park IS, Park KB, et al. Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc 2009;46:239–44.
- Cho WS, Kang HS, Kim JE, et al. Intra-arterial nimodipine infusion for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Interv Neuroradiol 2011;17:169–78.
- Hänggi D, Turowski B, Beseoglu K, et al. Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid hemorrhage: influence on clinical course and cerebral perfusion. Am J Neuroradiol 2008;29:1053–60.
- McGuinness B, Gandhi D. Endovascular management of cerebral vasospasm. Neurosurg Clin N Am 2010;21:281–90.
- Vergouwen Mervyn DI, Vermeulen M, Gijn JV, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies. Stroke 2010;41:2391–5.
- Kosnik EJ, Hunt WE. Postoperative hypertension in the management of patients with intracranial arterial aneurysms. J Neurosurg 1976;45:148–54.
- Kassell NF, Peerless SJ, Durwood QJ, et al. Treatment of ischaemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 1982;11:337–43.
- Solenski NJ, Haley EC, Kassell NF, et al. Medical complications of subarachnoid haemorrhage: a report of the multicentre, cooperative aneurysm study. Participants of the multicentre cooperative aneurysm study. Crit Care Med 1995;23:1007–17.
- Mukherjee KK, Singh SK, Khosla VK, et al. Safety and efficacy of sildenafil citrate in reverasal of cerebral vasospasm: a feasibility study. Surg Neurol Int 2012;3:3.
- Bele S, Proescholdt MA, Hochreiter A, et al. Continuous intra-arterial nimodipine infusion in patients with severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a feasibility study and outcome results. Acta Neurochir (Wien) 2015;157:2041–50
- Pickard JD, Walker V, Vile J, et al. Oral nimodipine reduces prostaglandin and thromboxane production by arteries chronically exposed to a periarterial haematoma and the antifibrinolytic agent tranexamic acid. J Neurol Neurosurg Psychiatry 1987;50:727–31.
- Rasmussen G, Bergholdt B, Dalh B, et al. Effect of nimodipine on cerebral blood flow and cerebrovascular reactivity after subarachnoid haemorrhage. Acta Neurol Scand 1999;99:182–6.
- Roda JM, Carceller F, Díez-Tejedor E, et al. Reduction of infarct size by intra-arterial nimodipine administered at reperfusion in a rat model of partially reversible brain focal ischemia. Stroke 1995;26:1888–92.
- Ramsch KD, Graefe KH, Scherling D, et al. Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. Am J Nephrol 1986;6:73–80.
- Ramsch KD, Ahr G, Tettenborn D, et al. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia 1985;28:74–8.